top of page

DEEP TECH | INDEPENDENT PROGRAMME REVIEW & COMMERCIALISATION STRATEGY​

Decisions that
stand up to scrutiny

I help institutions and science-based ventures decide what to fund, change or stop – by connecting technical evidence, commercial realities and capital requirements. Start with a focused decision review in 2-3 weeks.

Our innovation programme has supported several deep tech pilots, but few have become repeatable revenue. How can we tell whether the barrier is the technology, customer demand, the venture’s sales approach, or our programme design?

Science Commercialisation:
When Generic Startup Playbook Fails

Progress in one area can conceal a constraint in another.

A programme can meet its targets without showing what its support changed. A technology can work while qualification, customer adoption or financing blocks its route to market. Before committing more resources, identify what is holding back the next step – and what evidence would justify moving forward.

Understand how the parts interact – and what that changes about your next decision..png

Innovation programme evaluation for funders and institutions

What did your programme change, and what deserves another funding period?

Explore Institutional Work

Commercialisation strategy for scaleups and technology-led SMEs

What must become true before your next commercial or financing commitment?

Explore Commercial Work

The Deep Tech Innovation Friction

The risk in science commercialisation lies in committing more resources before the real constraint is understood. I help reducing that risk through looking beyond individual performance measures.

I analyse how technical, commercial and institutional factors interact, what second-order effects can emerge later, and how to navigate them.

​​

QUATISE® is the proprietary methodology behind my work. It helps me examine how factors – that are usually assessed in silos – affect one another, identify what is limiting progress and turn complex evidence into a decision you can act on.

Our university spinout has strong research results but limited market traction. What evidence should the team gather before seeking investment, and how should we assess whether follow-on funding is justified?

Independent expertise.
A clear point of view.

Hi, I'm Maria Ksenia Witte

Scientist and commercialisation expert working independently, connecting science, commercial strategy and capital. Through Arise Innovations®, I help institutions and ventures turn complex evidence into decisions they can act on.

 

250+ cases assessed · 25+ programmes & ecosystems

€100M+ allocation exposure

 

My QUATISE® methodology is built on formally certified applied RD&I under OECD Frascati criteria (validated through the German Federal Ministry of Research, Technology and Space).

Newsletter
Briefs

Analysis of the decisions connecting science, commercialisation, capital and policy.

Each brief examines a consequential question, the evidence behind it and what it could change about the next move.

bottom of page